scholarly journals Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development

2015 ◽  
pp. 1001 ◽  
Author(s):  
Quan Nguyen ◽  
Aniruddha Agarwal ◽  
William Rhoades ◽  
Mostafa Hanout ◽  
Mohamed Soliman ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
State Of The Art ◽  
Age Related Macular Degeneration ◽  
Visual Outcomes ◽  
Current State ◽  
Age Related

scholarly journals Ten-year survival trends of neovascular age-related macular degeneration at first presentation

2020 ◽  
pp. bjophthalmol-2020-317161
Author(s):  
Cristina Arpa ◽  
Hagar Khalid ◽  
Shruti Chandra ◽  
Siegfried Wagner ◽  
Katrin Fasler ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Visual Outcomes ◽  
Anti Vegf ◽  
Kaplan Meier ◽  
Age Related ◽  
Treatment Naïve ◽  
Mean Trend ◽  
Endothelial Growth Factor ◽  
Good Vision

BackgroundTo describe 10-year trends in visual outcomes, anatomical outcomes and treatment burden of patients receiving antivascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD).MethodsRetrospective cohort study of treatment-naïve, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. The primary outcome was time to best-corrected visual acuity (BCVA) falling ≤35 ETDRS letters after initiating anti-VEGF therapy. Secondary outcomes included time to BCVA reaching ≥70 letters, proportion of eyes with BCVA ≥70 and ≤35 letters in 10 years, mean trend of BCVA and central retinal thickness over 10 years, and mean number of injections.ResultsFor our cohort of 103 patients, Kaplan-Meier analyses demonstrated median time to BCVA reaching ≤35 and ≥70 letters were 37.8 (95% CI 22.2 to 65.1) and 8.3 (95% CI 4.8 to 20.9) months after commencing anti-VEGF therapy, respectively. At the final follow-up, BCVA was ≤35 letters and ≥70 letters in 41.1% and 21%, respectively, in first-affected eyes, while this was the case for 5.4% and 48.2%, respectively, in a patient’s better-seeing eye. Mean injection number was 37.0±24.2 per eye and 53.6±30.1 at patient level (63.1% of patients required injections in both eyes).ConclusionsThe chronicity of nAMD disease and its management highlights the importance of long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet, one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes.

scholarly journals Effect of retinal thickness variability on visual outcomes and fluid persistence in neovascular age-related macular degeneration

Retina ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Pravin U. Dugel ◽  
Chirag D. Jhaveri ◽  
Usha Chakravarthy ◽  
Charles C. Wykoff ◽  
Rishi P. Singh ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Retinal Thickness ◽  
Age Related Macular Degeneration ◽  
Visual Outcomes ◽  
Age Related ◽  
Thickness Variability

State-of-the art pharmacotherapy for non-neovascular age-related macular degeneration

2020 ◽  
Vol 21 (7) ◽  
pp. 773-784 ◽  
Author(s):  
Daniele Veritti ◽  
Valentina Sarao ◽  
Francesco Samassa ◽  
Carla Danese ◽  
Anat Löwenstein ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
State Of The Art ◽  
Age Related Macular Degeneration ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document